CD69 Antibody, anti-human, REAfinity™
Synonyms: AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3, VEA
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
89 Citations22 Images
Clone:
REA824 | FN50
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD69 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 615
PE-Vio 670
PE-Vio 770
PerCP-Vio 700
Vio Bright B515
Vio Bright R720
Vio Bright V600
Vio Bright V646
VioBlue
VioGreen
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-112-803, 130-112-614
Description:
Human peripheral blood mononuclear cells (PBMCs), either left unstimulated (left image) or stimulated with CytoStim, were stained with CD69 antibodies as well as with CD4 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
PE
Fixation:
frozen – Acetone
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:40
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-112-613, 130-112-802
Testing grade:
Description:
Immunofluorescence analysis of a human tonsil cryosection fixed with ice-cold acetone. The section was stained using CD69 Antibody, anti-human, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue).Scale bar: 30 µm.

Application image
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-124-326
Extended validation for CD69 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA824
FN50
high
L78
high

Cells were incubated with an excess of purified unconjugated CD69 (REA824) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD69 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD69-PE (REA824, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD69 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD69-PE, clone (REA824). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD69. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 24 hours were stained with CD69 antibodies and with a suitable counterstaining. As a control, CD69 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD69 (REA824). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD69 Antibody, anti-human, REAfinity™
Overview

Clone REA824 recognizes the human CD69 antigen, also known as activation inducer molecule (AIM). CD69 is involved in the early events of lymphocyte, monocyte, and platelet activation. Cross-linking of CD69 induces cytotoxic activity and costimulates cytokine production of activated natural killer (NK) cells and selected T cell clones. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. It is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes.

Additional information: Clone REA824 displays negligible binding to Fc receptors.

Alternative names

AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3, VEA

Detailed product information

Technical specifications

Clone
REA824
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, non-human primate
Cross-reactivity
cynomolgus monkey (Macaca fascicularis), rhesus monkey (Macaca mulatta), baboon
Antigen
CD69
Molecular mass of antigen [kDa]
23
Distribution of antigen
B cells, Langerhans cells, leukocytes, lymphocytes, NK cells, platelets, T cells, neutrophils, thymocytes
Entrez Gene ID
RRID
AB_2811652, AB_2928550, AB_2905110, AB_2659072, AB_2905108, AB_2905109, AB_2659070, AB_2659062, AB_2659066, AB_2659071, AB_2659063, AB_2659075, AB_2659076, AB_2928549, AB_2659077, AB_2659067, AB_2659069, AB_2659073, AB_2905111, AB_2659068, AB_2659074, AB_2659079, AB_2659065, AB_2659078, AB_2659064

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD69 Antibody, anti-human, REAfinity™
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?